close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

57.88 +0.70 (+1.23%)
Delayed Quote Updated: 3:36 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad... 
Via StockStory
Topics Artificial Intelligence
News headline image
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
BIOMARIN PHARMACEUTICAL INC has a stellar value proposition. NASDAQ:BMRN not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
News headline image
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
News headline image
Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 19, 2025 ↗
 
Via Benzinga
News headline image
NASDAQ:BMRN, a growth stock which is not overvalued. ↗
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. 
Via Chartmill
News headline image
The Latest Analyst Ratings For Biomarin Pharmaceutical ↗
 
Via Benzinga
News headline image
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. 
Via StockStory
News headline image
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know. 
Via StockStory
News headline image
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today ↗
Via The Motley Fool
News headline image
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company reported impressive fourth-quarter results, exceeding analysts' sales and EPS... 
Via StockStory
News headline image
The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical ↗
 
Via Benzinga
News headline image
Why Is BioMarin Stock Trading Higher On Thursday? ↗
BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results. 
Via Benzinga
News headline image
BioMarin: EPS Surges Past Expectations ↗
BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. 
Via The Motley Fool
News headline image
BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 15.6% year on year to $747.3 million. The company’s full-year... 
Via StockStory
News headline image
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
News headline image
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. ↗
NASDAQ:BMRN is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
News headline image
NASDAQ:BMRN is an undervalued gem with solid fundamentals. ↗
Take a closer look at BIOMARIN PHARMACEUTICAL INC , a remarkable value stock. NASDAQ:BMRN excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill
News headline image
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,... 
Via Benzinga
News headline image
NASDAQ:BMRN is showing decent growth, but is still valued reasonably. ↗
Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators ↗
Alger launched its INVN ETF, with holdings including BioMarin, Teradata, and Bristol-Myers Squibb. 
Via Benzinga
Topics ETFs
News headline image
10 Magnificent Stocks That Can Make You Richer in 2025 ↗
A new year brings with it new opportunities to grow your wealth on Wall Street. 
Via The Motley Fool
News headline image
NASDAQ:BMRN stands out as a stock that provides good value for the fundamentals it showcases. ↗
In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. ↗
Despite its growth, NASDAQ:BMRN remains within the realm of affordability. 
Via Chartmill
News headline image
When you look at NASDAQ:BMRN, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon? 
Via MarketBeat
News headline image
NASDAQ:BMRN stands out as a growth opportunity that won't break the bank. ↗
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) is showing decent growth, but is still valued reasonably. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.